Department of Endoscopic Medicine, Mie University Hospital, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Int J Clin Oncol. 2018 Apr;23(2):243-248. doi: 10.1007/s10147-017-1201-3. Epub 2017 Oct 24.
Patients with head and neck cancer (HNC) have a high incidence of esophageal squamous cell neoplasms (ESCN). ESCN also has a negative impact on the survival of HNC patients. However, recent endoscopic advances enable the early detection of ESCN, and novel treatments may lead to improving survival rates for HNC patients with ESCN.
HNC patients who underwent magnifying esophagogastroduodenoscopy (EGDS) from 2005 to 2012 were included in this study (n = 226). We analyzed the prevalence and prognostic value of ESCN in HNC patients and the difference in overall survival between HNC patients with and without ESCN.
Thirty-four patients (15%) developed an ESCN during their clinical course. Of the 34 patients, 10 patients underwent endoscopic resection for ESCN and 10 patients underwent simultaneous chemoradiation therapy for HNC and ESCN. The 3-year survival rates in HNC patients with and without ESCN were 53% and 70%, respectively. Multivariate analysis identified the advanced clinical stage of the HNC [hazard ratio (HR) = 2.15; 95% confidence interval (CI) = 1.18-3.93; p = 0.012] and the presence of ESCN (HR = 1.73; 95% CI = 1.00-2.97; p = 0.049) as significant and independent determinants of overall survival.
Our study suggests that although the survival of HNC patients with ESCN may be improved by routine EGDS during tumor surveys and by advances in endoscopy, the presence of ESCN still remains an independent negative prognostic factor for HNC patients.
头颈部癌症(HNC)患者的食管鳞状细胞肿瘤(ESCN)发病率较高。ESCN 也对 HNC 患者的生存产生负面影响。然而,最近内镜技术的进步使得 ESCN 的早期检测成为可能,新的治疗方法可能会提高患有 ESCN 的 HNC 患者的生存率。
本研究纳入了 2005 年至 2012 年间接受放大食管胃十二指肠镜检查(EGDS)的 HNC 患者(n=226)。我们分析了 HNC 患者中 ESCN 的患病率和预后价值,以及有无 ESCN 的 HNC 患者总体生存率的差异。
34 例患者(15%)在其临床病程中发展出 ESCN。在这 34 例患者中,10 例患者因 ESCN 行内镜下切除术,10 例患者因 HNC 和 ESCN 行同期放化疗。有和无 ESCN 的 HNC 患者的 3 年生存率分别为 53%和 70%。多因素分析确定 HNC 的晚期临床分期(HR=2.15;95%置信区间[CI]为 1.18-3.93;p=0.012)和 ESCN 的存在(HR=1.73;95%CI 为 1.00-2.97;p=0.049)是总体生存率的显著独立决定因素。
本研究表明,尽管通过常规 EGDS 在肿瘤监测期间和内镜技术的进步可以改善患有 ESCN 的 HNC 患者的生存,但 ESCN 的存在仍然是 HNC 患者的独立负性预后因素。